Expert Directory
David G. Maloney, MD, PhD
- Professor Emeritus, Division of Translational Science and Therapeutics
- Fred Hutchinson Cancer Center
- Professor Emeritus of Medicine, Division of Medical Oncology
- University of Washington
- Seattle, WA
David G. Maloney, MD, PhD, received his MD and PhD in cancer biology from Stanford University, completed his internship and residency in internal medicine at Brigham and Woman’s Hospital, and completed a fellowship in oncology at Stanford University. He joined the faculties of Fred Hutchinson Cancer Center and the University of Washington in 1994. He is currently Professor Emeritus in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and Professor Emeritus of Medicine in the Division of Medical Oncology at the University of Washington.
Dr Maloney’s career research interests have been in the development of immunotherapies for patients with lymphoma, multiple myeloma, chronic lymphocytic leukemia, and acute lymphocytic leukemia. He has had a long-standing interest in the development and understanding of the mechanisms of action of monoclonal antibodies, and he was instrumental in the development and testing of rituximab while working with Ronald Levy, MD, at Stanford. Rituximab was the first US Food and Drug Administration–approved antibody-based cancer drug, and it has transformed the treatment of most B-cell malignancies. Working with Drs Storb and Sandmaier, nonmyeloablative conditioning for allogeneic transplantation was developed, which demonstrated the power of graft-vs-tumor activity from donor T cells and provided curative treatment for older patients who have comorbidities with better efficacy and lower toxicity.
For the past 10 years, Dr Maloney has focused on the development of CAR T-cell therapy, which combines tumor localization using an antibody fragment with the power of autologous T cells, increasing tumor cell destruction while avoiding graft-versus-host disease. He led the implementation of this new treatment into the clinic with the establishment of the Bezos Family Immunotherapy Clinic at Fred Hutchinson Cancer Center (legacy Seattle Cancer Care Alliance) 8 years ago. At the time, this was the first cellular immunotherapy clinic in the world. This clinic specializes in the administration of both commercial and research cellular immunotherapies. Currently, the major focus of research in this area is on the application of these treatments in patients with solid cancers.
Dr Maloney has amassed more than 290 publications in peer-reviewed journals in the areas of research described above. His care and commitment to patients is routinely acknowledged, most recently over the last 10 years when he was included in Newsweek’s "Top Cancer Doctors" and Castle Connolly's "America’s Top Doctors for Cancer," as well as when he was named by his peers as a "Top Doctor in Medical Oncology" in Seattle Magazine as recently as 2023.
Contributing Articles
No related "post" posts found.